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Social supportTB incidence and mortality in Belarus has been progressively falling from 54 to 41 and from
12.1 to 6.8 per 100000, accordingly, for the last 7 years. Nevertheless, the number of HIV/TB
co-infected rises dramatically. According to a recent nationwide drug resistance survey,
MDR-TB was found in 32.3% of new and in 75.6% of previously treated TB cases. Results
of treatment of MDR-TB are far from satisfactory (51% treatment success, 11% deaths).
Risk factors for MDR-TB acquisition and unfavorable treatment outcome are the follow-
ing: young age, drug and alcohol abuse, HIV, history of imprisonment, unemployment, and
homelessness. Most of such events as treatment failure and loss to follow-up occur at the
outpatient treatment phase, particularly in patients from the above-mentioned risk groups.
One of the key elements of outpatient care strengthening is social support.
Two operational research studies were conducted. One study with 40 MDR-TB patients
included showed that treatment cost can be reduced by more than 5200 US dollars per
patient using outpatient care with social support instead of existing care based on
long-term hospitalization. Another study showed that MDR-TB patients with social support
(n = 1057) had better treatment outcomes compared with conventionally managed
patients (n = 3514): treatment success 70% vs. 53%; mortality 2% vs. 6%; treatment failure
27% vs. 40%.
Along with adequate diagnostics and therapy, outpatient care strengthening and social
support are important elements in achieving good treatment outcomes and reducing the
cost of treatment of MDR-TB.
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